iRhythm Holdings Announces Acquisition of Vital Connect for $287.5M

What Happened
On August 5, 2026, iRhythm Holdings, Inc. entered into an Agreement and Plan of Merger to acquire Vital Connect, Inc. through a newly formed iRhythm subsidiary (Project Vessel Merger Sub). Under the Merger Agreement, Vital Connect will become a direct wholly owned subsidiary of iRhythm’s acquisition vehicle and an indirect wholly owned subsidiary of iRhythm. The aggregate consideration is $237.5 million in cash (subject to customary adjustments) plus $50 million of iRhythm common stock (shares issued based on the 30-day VWAP ending the trading day before the Merger Agreement). The parties expect the transaction to close by the end of 2026, subject to Vital Connect stockholder approval and expiration/termination of the Hart‑Scott‑Rodino antitrust waiting period.

Key Details

• Agreement date: August 5, 2026; parties include iRhythm Holdings, iRhythm Technologies, Project Vessel Merger Sub, Vital Connect, and Fortis Advisors (Stockholders’ Agent).
• Consideration: $237.5M cash + $50M in iRhythm common stock (aggregate ≈ $287.5M), subject to purchase price adjustments; portion held in escrow for post‑closing adjustments and indemnities.
• Securities treatment: outstanding Vital Connect stock options and certain warrants will be cancelled without consideration (vested/in‑the‑money warrants treated per agreement).
• Conditions and protections: closing subject to target stockholder approval and HSR clearance; Acquirer may pay a $9.0M reverse termination fee in specified antitrust‑related termination scenarios.
• Interim funding: iRhythm will provide interim grants to Vital Connect to fund operations pre‑closing, starting with $10.0M and up to $30.0M total.

Why It Matters
This is a material acquisition for iRhythm: it brings Vital Connect into iRhythm’s corporate structure and involves both cash and stock consideration, which may affect iRhythm’s cash position and share count. The deal is subject to customary closing conditions (including shareholder and antitrust approvals), escrow for post‑closing adjustments, and an interim funding arrangement that supports Vital Connect’s operations before closing. Investors should watch for regulatory clearance, the target shareholder vote, and subsequent disclosures about integration plans and any purchase price adjustments.